Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

• Status: Terminated
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Determine the effect of treatment with INCB019602 administered as an add-on to stable dose metformin therapy in type 2 diabetic subjects on safety and glycemic control.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Incyte Corporation
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Established diagnosis of T2D

• Currently taking metformin monotherapy at a stable dose level

• FPG between 150 and 270 mg/dL

Exclusion Criteria:

• History or clinical manifestations of renal impairment

• Hyperglycemia > 270 mg/dL

• Receiving thiazolidenediones, Exenatide or sulfonylureas within 90 days prior to screening

• Prior use of Acipimox which is known under the name Olbetam within 90 days prior to screening.

• Diagnosed major depression within the last 2 years requiring hospitalization

• History of chronic insulin therapy for glycemic control